Semuloparin (a new LMWH) reduced DVT & PE in chemotherapy patients (RCT, NEJM)
www.pulmccm.org
For unclear reasons, people receiving chemotherapy for solid tumors are at particularly increased risk for deep venous thrombosis and pulmonary embolism (DVT/PE). Semuloparin is an ultra-low-molecular weight heparin with a long half life of 16-20 hours that (like enoxaparin) is renally excreted.
Semuloparin (a new LMWH) reduced DVT & PE in chemotherapy patients (RCT, NEJM)
Semuloparin (a new LMWH) reduced DVT & PE in…
Semuloparin (a new LMWH) reduced DVT & PE in chemotherapy patients (RCT, NEJM)
For unclear reasons, people receiving chemotherapy for solid tumors are at particularly increased risk for deep venous thrombosis and pulmonary embolism (DVT/PE). Semuloparin is an ultra-low-molecular weight heparin with a long half life of 16-20 hours that (like enoxaparin) is renally excreted.